icon
icon
icon
icon
Upgrade
icon

The FDA recommended halting the use of common decongestants in cold medicines, which could affect companies such as GSK (US).

AInvestFriday, Nov 8, 2024 5:20 am ET
1min read

The US Food and Drug Administration said on Thursday it had proposed to remove oral phenylephrine, a common ingredient in cough and cold syrups, from the list of active ingredients in over-the-counter nasal decongestants and called it ineffective. The ingredient is widely used in various over-the-counter flu and cold medicines, including popular products such as Benadryl, Advil and Tylenol, and is also a component in nasal sprays for treating nasal congestion. However, the FDA's action only involves oral administration of phenylephrine, not nasal sprays.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.